|
Vitamin D Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
The logistic regression model showed that vitamin D deficiency was a predictor for the presence of CEA (P = 0.013).
|
30221529 |
2018 |
|
Venous Thromboembolism
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In this retrospective study of 173 individuals with a diagnosis of either colorectal, pancreatic, or ovarian Cancer, higher tumor marker levels (CEA, CA 19-9, and CA 125 respectively) were associated with an increased risk of VTE, either DVT or PE.
|
28470575 |
2018 |
|
VASCULAR EMBOLISM
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with vascular embolism had higher serum levels of CEA, CA19-9, CA24-2, and CA72-4 compared with patients without vascular embolism (p=0.005, p=0.031, p=0.007, and p=0.014, respectively).
|
23787496 |
2013 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
His treatment was then switched to anti-PD-L1 therapy with atezolizumab as it was approved for urothelial carcinoma at that time, and his CEA declined again.
|
28726535 |
2017 |
|
Urinary Bladder Calculi (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Surgical history, incidence of urinary tract infection (UTI) and bladder stones, vesicoureteral reflux (VUR), urine cytology, renal function, a colon cancer tumor marker (carcinoembryonic antigen: CEA), and patient outcomes were assessed.
|
29223546 |
2017 |
|
Urachal cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum markers like CEA, CA19-9 and CA125 might additionally be useful in the follow-up and monitoring of UrC.
|
29721106 |
2018 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Many polyps and dysplastic lesions in ulcerative colitis have phenotypic changes (blood group antigen, cytokeratins, CEA, TAG-72.3 antigen expression) and genetic changes (c-K-ras mutation, enhanced c-myc expression and pp60c-src activity) which are characteristic of invasive cancers.
|
3052255 |
1988 |
|
Tumour budding
|
0.010 |
Biomarker
|
disease |
BEFREE |
Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer.
|
28478638 |
2017 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CEA has been shown to have surprisingly diverse functions in cell adhesion, intracellular and intercellular signaling, and complex biological processes such as cancer progression, inflammation, angiogenesis, and metastasis.
|
31828452 |
2020 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Most patients demonstrated tumor progression by clinical and radiographic parameters and by CEA levels.Immune assays are pending.
|
8876893 |
1996 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
A prominent example is CEACAM5 (CEA, CD66e), where the shed domain plays a pivotal role in tumor progression and metastasis.
|
31447859 |
2019 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CEA and E-cadherin expressions were simultaneously assessed with regard to tumor progression in the various sites of colorectal carcinomas with liver metastasis.
|
14592671 |
2003 |
|
Tumor Immunity
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination.
|
15855015 |
2005 |
|
Tumor Immunity
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The gene therapy approaches being employed can be divided into three major categories: (1) enzyme/prodrug systems (HSVtk/ganciclovir; CD/5-fluorocytosine); (2) tumor suppressor gene replacement therapy with wild-type p53; and (3) immune-gene therapy which is based on cytokine or tumor antigen expression to induce tumor immunity (e.g., CEA).
|
9684100 |
1998 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
There were no significant differences in gender, perineural invasion as well as serum levels of CEA, CA724 and CA242.
|
31375274 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Methylation of <i>ZIC1</i> was associated with positive serum CA19-9, while that of <i>HOXD10</i> was related to H. pylori status, serum CA19-9 and CEA levels and tumor invasion depth.
|
28529617 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CEA crossing-point values (CEA-CP) were significantly correlated with the depth of tumor invasion and the values were cut-off at 27.11, which was the minimum value of mucosal cancer patients.
|
12820444 |
2003 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Besides, positive galectin-3 expression was also related to advanced TNM stages(III/IV vs. I/II: OR 5.30, 95% CI: 2.42-11.61, P < 0.0001), higher Duke's stages (C/D vs. A/B: OR 4.00, 95% CI: 2.22-7.22, P < 0.0001), venous invasion (venous invasion vs. not: OR 3.02, 95%CI: 1.75-5.22, P < 0.0001) and higher CEA level (CEA≥5 ng/ml vs. ≤ 5 ng/ml: OR 2.09, 95% CI: 1.09-4.03, P = 0.03).
|
31474314 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Regarding overall survival, on univariate analysis the following variables were significantly associated with poor outcome following resection: T-stage (<i>P</i> = 0.037), lymph node invasion (<i>P</i> = 0.037), cancer stage (<i>P</i> = 0.034), CEA (<i>P</i> = 0.042), CA19-9 (<i>P</i> = 0.004), and PNI (<i>P</i> = 0.001).
|
28808503 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The upregulated NEDD9 expression in gastric cancer tissue was significantly correlated with high preoperative CEA level (P = 0.044), poor differentiation (P = 0.007), tissue invasion (P = 0.015), present lymph node metastasis (P < 0.001), and high TNM stage (P < 0.001).
|
24664584 |
2014 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor deposit were significantly correlated with T-stage(P=<0.001), N-stage(P=<0.001), PLNC(P=<0.001), venous invasion(P=<0.001), TNM staging(P=<0.001), CEA(P=0.021) and CA19-9(P=0.042) of primary tumor.
|
30410602 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
CEA mRNA was detected in the drainage venous blood from 11 (42%) of 26 patients, and the rate of detection increased according to the grade of vessel invasion.
|
9697262 |
1998 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
On multivariate analysis, serum CEA level [hazard ratio (HR) =1.040, P=0.046] and lymphovascular invasion (HR =2.664, P=0.027), but not wedge resection, were significant risk factors for recurrence in stage IA2 NSCLC.
|
31372273 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Besides, hsa_circ_0067582 expression was associated with GC patients' tissue CEA level (P <.001) and stages (P = .037); and hsa_circ_0005758 expression was relevant to tissue CEA level (P < .001) and perineural invasion (P = .048).
|
31328820 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Forty-eight of 98 patients were CTCs-positive, including 18 CTM-positive patients, and CTC detection was positively correlated with lymphatic invasion (<i>P</i> = 0.049), TNM stage (<i>P</i> = 0.023), and serum CEA level (<i>P</i> = 0.014).
|
28070168 |
2017 |